Genfit Archives

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. …

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 13 May 2020

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed.…

May 13, 2020 - 4 minutesmins - By Helen Albert

Interview 30 Jul 2019

The First Approved NASH Therapy?

Genfit is poised to become the first company to get a treatment for NASH to market -- something that could happen as early as 2020, should its late 2019 phase…

July 30, 2019 - 6 minutesmins - By Helen Albert

nash liver fibrosis genfit terns pharmaceuticals organ

News and Trends 25 Jun 2019

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH in China. As part of the deal, Genfit will receive…

June 25, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 27 Mar 2019

Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M

After some big failures from its top competitors earlier this year, French company Genfit has done an IPO to prepare the launch of its drug for NASH, a chronic liver…

March 27, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jan 2018

NASH Leader goes Pediatric with Clinical Trial Launch in US

The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and inflammatory diseases,…

January 23, 2018 - 2 minutesmins - By Alex Dale

Best in Biotech 28 Dec 2017

Bored Between the Holidays? Watch these Biotech Videos!

Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It's vacation time! If you've worn…

December 28, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 17 Oct 2017

Genfit Gets €180M Cash Injection to Bring its Pipeline to Market

Elafibranor, Genfit's lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for…

October 17, 2017 - 3 minutesmins - By Alex Dale

Best in Biotech 26 Sep 2017

These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare

Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,”…

September 26, 2017 - 8 minutesmins - By Evelyn Warner

Interview 11 Jul 2017

The Advantage for the First Mover in NASH is Limited, says Genfit

After we reviewed NASH earlier this year, Genfit's CSO, Dean Hum, came to speak at Refresh about his company's strategy in the space. As CSO of Genfit, Dean Hum coordinates…

July 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 24 Apr 2017

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech…

April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Apr 2017

Two Big Pharma Players Team up to Take Over the NASH Space

Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis' FXR agonist for NASH. After Allergan snapped up Tobira's cenicriviroc (CVC) last year in…

April 18, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 28 Mar 2017

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first…

March 28, 2017 - 5 minutesmins - By Evelyn Warner

In Depth 7 Feb 2017

Not to be Underestimated: What’s the Hype around NASH?

Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of immuno-oncology. What’s it all about? [caption id="attachment_40895" align="alignleft" width="148"] Jean-Christophe Marcoux[/caption] “NASH is a well-recognized…

February 7, 2017 - 10 minutesmins - By Evelyn Warner

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016…

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Green Light for Genfit to Tackle another Liver Disease

The FDA has cleared Genfit's IND application to treat a second liver disease with a big unmet clinical need. With this new step forward, the company gets even closer to…

November 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Genfit reinforced its leading place in the race to find a cure for NASH when it announced this morning the launch of a program to validate their new diagnostic tool. Genfit is already…

September 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

genfit primary billiary cholangitis elafibranor

News and Trends 31 Mar 2016

Beyond NASH: Genfit jumps into another Critical Liver Condition

Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease - Primary Biliary Cholangitis (PBC), a rare condition with high unmet medical needs. Genfit from Lille…

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

genfit nash fatty liver disease elfibranor PPAR phase III resolve it

News and Trends 11 Mar 2016

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment. This is good news for…

March 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 12 Jan 2016

10 Hot European Biotechs to watch in 2016

Looking forward to 2016, I wondered which Biotechs I would watch closely. Here's my list (which is not meant to be extensive and is in no particular order): 1. Immunocore…

January 12, 2016 - 6 minutesmins - By Philip Hemme

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering